Table 2 Clinical characteristics of female ERA subgroups divided according to the median of CVAI (65.73).

From: A novel visceral adiposity index predicts bone loss in female early rheumatoid arthritis patients detected by HR-pQCT

 

Low CVAI (n = 52)

High CVAI (n = 52)

P value

ESR (mm/h)

55.52 ± 27.52

73.63 ± 34.49

0.004

CRP (mg/L)

18.09 ± 21.09

24.58 ± 31.76

0.222

Disease duration (month)

8.0 ± 5.0

9.0 ± 7.0

0.414

RF titer

0.69 ± 0.47

0.92 ± 0.27

0.003

ACCP titer

0.92 ± 0.27

0.81 ± 0.40

0.087

HAQ (0–3)

0.93 ± 0.63

1.31 ± 0.77

0.007

Tender joint count (0–68)

8 (5.12)

8 (5.13)

0.601

Swollen joint count (0–66)

6 (2.8)

4 (36.75)

0.216

Damage joint count (0–68)

1.5 (0.252)

2 (1.4)

0.026

DAS 28-CRP

4.94 ± 1.08

5.06 ± 0.85

0.536

SDAI score

29.87 ± 12.80

29.64 ± 10.54

0.921

Patient VAS global assessment

6.34 ± 1.82

6.19 ± 1.72

0.678

Biologic DMARDs

0

0

–

MTX (%)

6 (11.54)

3 (5.77)

0.319

Leflunomide (%)

1 (1.92)

0

1.000

Sulfasalazine (%)

1(1.92)

1(1.92)

–

Hydroxychloroquine (%)

4 (7.69)

2 (3.85)

0.402

Glucocorticord (%)

12 (23.08)

7 (13.46)

0.310

NSAIDs use (%)

43 (82.69)

39 (75)

0.472

  1. CVAI: Chinses visceral adiposity index; low CVAI group (< 65.73); high CVAI group (≥ 65.73). ERA: early rheumatoid arthritis; ESR: erythrocyte sedimentation rate; CRP: C- response protein; RF: rheumatoid factor; ACCP: Autoantibodies binding to citrullinated antigens; HAQ: Health Assessment Questionnaire; DAS 28-CRP: Disease Activity Score in 28 joint for CRP; CRP: C- response protein; SDAI: Simple Disease Activity Index Score; VAS: visual analogue scale. NSAIDs: non-steroidal anti-inflammatory drugs. P value: low CVAI & high CVAI.
Back to article page